Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes? Response

被引：0
|
作者：
Bennett, Melanie E. [1 ]
Calkins, Monica E. [2 ,3 ]
Dickerson, Faith [4 ]
Kreyenbuhl, Julie [1 ]
Medoff, Deborah [1 ]
机构：
[1] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD USA
[2] Univ Penn, Perelman Sch Med, Penn Early Intervent Ctr PE HeadsUp, Dept Psychiat,Neurodev & Psychosis Sect, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Dept Psychiat, Neurodev & Psychosis Sect, Philadelphia, PA USA
[4] Sheppard Pratt, Dept Psychol, Baltimore, MD USA
来源：
SCHIZOPHRENIA RESEARCH | 2024年 / 270卷
关键词：
D O I：
10.1016/j.schres.2024.06.012
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [1] Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
    Jacobsen, Soren L.
    Kohler-Forsberg, Ole
    Rohde, Christopher
    SCHIZOPHRENIA RESEARCH, 2024, 270 : 231 - 234
  • [2] Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
    Shin, Jung-Im
    CURRENT DIABETES REPORTS, 2019, 19 (08)
  • [3] Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
    Jung-Im Shin
    Current Diabetes Reports, 2019, 19
  • [4] Newer second-line glucose-lowering drugs versus thiazolidinediones and cirrhosis risk in type 2 diabetes
    Yang, Jeff Y.
    Alexopoulos, Anastasia
    Moon, Andrew M.
    Kim, Hannah
    Pate, Virginia
    Barritt, A. Sidney
    Sturmer, Til
    Buse, John B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 606 - 606
  • [5] Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Gu, Shuyan
    Hu, Xiaoqian
    Zhen, Xuemei
    Shi, Lizheng
    Shao, Hui
    Sun, Xueshan
    Gu, Yuxuan
    Huang, Minzhuo
    Dong, Hengjin
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [6] Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
    Yang, Jeff Y.
    Moon, Andrew M.
    Kim, Hannah
    Pate, Virginia
    Barritt, A. Sidney
    Crowley, Matthew J.
    Buse, John B.
    Sturmer, Til
    Alexopoulos, Anastasia-Stefania
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (11)
  • [7] Quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: the global DISCOVER study
    Nicolucci, A.
    Gomes, M. B.
    Khunti, K.
    Kosiborod, M.
    Pocock, S.
    Rathmann, W.
    Shestakova, M. V.
    Shimomura, I.
    Watada, H.
    Chen, H.
    Cid-Ruzafa, J.
    Fenici, P.
    Hammar, N.
    Tang, F.
    Ji, L.
    DIABETOLOGIA, 2018, 61 : S173 - S174
  • [8] Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes RESPONSE
    Tsapas, Apostolos
    Karagiannis, Thomas
    Avgerinos, Ioannis
    Matthews, David R.
    Bekiari, Eleni
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (01) : 141 - 141
  • [9] Future glucose-lowering drugs for type 2 diabetes
    Bailey, Clifford J.
    Tahrani, Abd A.
    Barnett, Anthony H.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (04): : 350 - 359
  • [10] Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study
    Nicolucci, Antonio
    Chen, Hungta
    Cid-Ruzafa, Javier
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Leigh, Paul
    Medin, Jennie
    Rathmann, Wolfgang
    Shestakova, Marina, V
    Shimomura, Iichiro
    Siddiqui, Afrah
    Tang, Fengming
    Watada, Hirotaka
    Ji, Linong
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 180
12345